A Questionnaire-based Study of the Views of Schizophrenia Patients and Psychiatric Healthcare Professionals in Japan about the Side Effects of Clozapine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: It is well documented that clozapine treatment causes agranulocytosis, but it can also induce drowsiness, constipation, and hypersalivation; however, these symptoms are usually less severe. It has been reported that clozapine-treated patients with schizophrenia and psychiatric healthcare professionals consider different side effects to be important. The aim of this study was to assess current practice related to the side effects of clozapine in clozapine-treated patients with schizophrenia and psychiatric healthcare professionals in Japan. Methods: Data were collected from January 2014 to August 2015 in Okehazama Hospital, Kakamigahara Hospital, and Numazu Chuo Hospital. Clozapine-treated patients with schizophrenia and psychiatric healthcare professionals (psychiatrists and pharmacists) were enrolled in this study. Results: Of the 106 patients and 120 psychiatric healthcare professionals screened, 100 patients and 104 healthcare professionals were included in this study. We asked the patients what side effects caused them trouble and we asked psychiatric healthcare professionals what side effects caused them concern. The patients and psychiatrists held similarly positive views regarding the efficacy of clozapine. The healthcare professionals were concerned about agranulocytosis (92.4%), blood routines (61.3%). On the other hand, the patients experienced hypersalivation (76.0%), sleepiness (51.0%). A positive correlation (R=0.696) was found between patient satisfaction and DAI-10 score. Conclusion: Patients experienced more problems than healthcare professionals expected. However, usage experience of clozapine healthcare professionals tended to have similar results to patients. It is necessary that all healthcare professionals fully understand the efficacy and potential side effects of clozapine. This is very important for promoting clozapine treatment in Japan.
Abstract
Objective: It is well documented that clozapine treatment causes agranulocytosis, but it can also induce drowsiness, constipation, and hypersalivation; however, these symptoms are usually less severe. It has been reported that clozapine-treated patients with schizophrenia and psychiatric healthcare professionals consider different side effects to be important. The aim of this study was to assess current practice related to the side effects of clozapine in clozapine-treated patients with schizophrenia and psychiatric healthcare professionals in Japan. Methods: Data were collected from January 2014 to August 2015 in Okehazama Hospital, Kakamigahara Hospital, and Numazu Chuo Hospital. Clozapine-treated patients with schizophrenia and psychiatric healthcare professionals (psychiatrists and pharmacists) were enrolled in this study. Results: Of the 106 patients and 120 psychiatric healthcare professionals screened, 100 patients and 104 healthcare professionals were included in this study. We asked the patients what side effects caused them trouble and we asked psychiatric healthcare professionals what side effects caused them concern. The patients and psychiatrists held similarly positive views regarding the efficacy of clozapine. The healthcare professionals were concerned about agranulocytosis (92.4%), blood routines (61.3%). On the other hand, the patients experienced hypersalivation (76.0%), sleepiness (51.0%). A positive correlation (R=0.696) was found between patient satisfaction and DAI-10 score. Conclusion: Patients experienced more problems than healthcare professionals expected. However, usage experience of clozapine healthcare professionals tended to have similar results to patients. It is necessary that all healthcare professionals fully understand the efficacy and potential side effects of clozapine. This is very important for promoting clozapine treatment in Japan.
참고문헌 (20)
- Conley RR, "Evaluation of treatment-resistant schizophrenia", Schizophr Bull, 23, pp.663~674 (1997)
- Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
- Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
- Alvir JM, "Agranulocytosis: incidence and risk factors", J Clin Psychiatry, 55(Suppl B), pp.137~138 (1994)
- Davydov L, "Clozapine-induced hypersalivation", Ann Pharmacother, 34, pp.662~665 (2000)
- Stroup TS, "Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia", Am J Psychiatry, 173, pp.166~173 (2016)
- Nielsen J, "Psychiatrists’attitude towards and knowledge of clozapine treatment", J Psychopharmacol, 24, pp.965~971 (2010)
- Hodge K, "Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians", Int J Ment Health Nurs, 17, pp.2~8 (2008)
- Day JC, "A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients", Br J Psychiatry, 166, pp.650~653 (1995)
- Howes OD, "Adherence to treatment guidelines in clinical practice:study of antipsychotic treatment prior to clozapine initiation", Br J Psychiatry, 201, pp.481~485 (2012)
- Valenstein M, "Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission", Med Care, 40, pp.630~639 (2002)
- Kane JM, "Management strategies for the treatment of schizophrenia", J Clin Psychiatry, 60(Suppl 12), pp.13~17 (1999)
- Sweileh WM, "Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia", Curr Clin Pharmacol, 7, pp.49~55 (2012)
- Hogan TP, "A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity", Psychol Med, 13, pp.177~183 (1983)
- David AS, "Insight and psychosis", Br J Psychiatry, 156, pp.798~808 (1990)
- Angermeyer MC, "Patients’ and relatives’ assessment of clozapine treatment", Psychol Med, 31, pp.509~517 (2001)
- Zeng XP, "Muscarinic m4 receptor activation by some atypical antipsychotic drugs", Eur J Pharmacol, 321, pp.349~354 (1997)
- Kishi T, "Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia:results from a 12-week, flexible dose study using raters masked to antipsychotic choice", Asian J Psychiatr, 6, pp.200~207 (2013)
- McKane JP, "Hyoscine patches in clozapine-induced hypersalivation", Psychiatr Bull, 25, pp.277~ (2001)
- Ippei Takeuchi, "Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series", Clinical Psychopharmacology and Neuroscience, 13(1), pp.109~112 (2015), 대한정신약물학회